Peptides / Weight and metabolic

Synthetic analog · 68 amino acids · 7,846.7 Da

Amycretin

Not approved

Amycretin, also called zenagamtide, is an experimental drug that acts on GLP-1 and amylin receptors, in phase 3 trials and not approved. Studies in people tested it for weight loss in obesity and blood sugar in type 2 diabetes, and tracked side effects. PepBank shows 21 results on amycretin from 4 studies in people, and 9 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as NNC0487-0111, Zenagamtide

First 40 of 68 amino acids3 changed amino acids

Evidence level: Large trials in people21 of 30 results come from studies in people, including randomized trials.

Results in people

70% of 30 results

Results in animals

20% of 30 results

Results in lab cells

10% of 30 results

From computer models

0% of 30 results

Overview

Amycretin at a glance

What it is	Synthetic analog, 68 amino acids
Approval	Not approved for any use
In sport	Status unknown
Studies	6 studies with results. 5 of them gave amycretin, with 30 results. 21 in people6 in animals3 in lab cells
Best study in people	Randomized controlled trial with 75 people (2026)
Clinical trials	31 registered: 22 active or planned, 0 with posted results

The science

What is amycretin?

A GLP-1 and amylin receptor co-agonist studied for obesity and type 2 diabetes.

Amino acids in one chain

The history of amycretin

2024
The oldest paper on amycretin in PepBank is from 2024.
2026February
A registered trial of amycretin started (NCT07339423).

Amycretin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 68 amino acidsFrom the first amino acid to the last

H1X−EGT5FTS−DV10SSYL−E15−EQAA+R20−EFIAW25LV+RG+R30+KGGGG35−EAS−EL40STAAL45G+RLSA50−ELH−EL55ATLP+R60T−ETGS65GSP

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Amycretin is a synthetic analog of 68 amino acids, with no ring, 3 changed amino acids.

Formula

C₃₄₃H₅₅₀N₉₄O₁₁₆

Molecular weight

7,846.7 g/mol

CAS number

3005889-81-3

Targets

GLP1R (gene GLP1R): agonistEvidence: Primary identity or pharmacology sourceCALCR (gene CALCR): agonistEvidence: Primary identity or pharmacology source

Development

Novo Nordisk. Highest phase: phase 3.

Identifiers

UNII T2EA5S9XJ5

Full sequence, SMILES and InChIKey

Three-letter sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Glu-Gln-Ala-Ala-Arg-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Lys-Gly-Gly-Gly-Gly-Glu-Ala-Ser-Glu-Leu-Ser-Thr-Ala-Ala-Leu-Gly-Arg-Leu-Ser-Ala-Glu-Leu-His-Glu-Leu-Ala-Thr-Leu-Pro-Arg-Thr-Glu-Thr-Gly-Ser-Gly-Ser-Pro

See charge, composition and 3D structure on the Scientific page

The evidence

What amycretin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people21 of 30 results come from studies in people, including randomized trials.

Weight and appetite

6 results · 4 in people · 2 animal

In participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 36 in Part B. Lancet, 2025

Top results

In participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 36 in Part B. (Lancet, 2025)
In rats with diet-induced obesity, amycretin reduced energy intake compared with vehicle. (EBioMedicine, 2025)
In participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 36 in Part C. (Lancet, 2025)

Blood sugar

3 results · 2 in people · 1 animal

In adults with type 2 diabetes, zenagamtide at 0·4 mg lowered HbA1c more than placebo at week 36. Lancet, 2026

Top results

In adults with type 2 diabetes, zenagamtide at 0·4 mg lowered HbA1c more than placebo at week 36. (Lancet, 2026)
In adults with type 2 diabetes, zenagamtide at 40 mg lowered HbA1c more than placebo at week 36. (Lancet, 2026)
In rats with diet-induced obesity, amycretin improved insulin sensitivity compared with vehicle. (EBioMedicine, 2025)

Survival and serious illness

2 results · 2 in people

In the oral amycretin trial, no participants died. Lancet, 2025

Top results

In the oral amycretin trial, no participants died. (Lancet, 2025)
In the zenagamtide trial, no participants died. (Lancet, 2026)

Liver

1 result · 1 animal

In rodents, amycretin improved fatty-liver features, mainly through reduced liver fat. EBioMedicine, 2025

Top results

In rodents, amycretin improved fatty-liver features, mainly through reduced liver fat. (EBioMedicine, 2025)

Metabolism and nutrition

1 result · 1 animal

In rats with diet-induced obesity, amycretin maintained energy expenditure. EBioMedicine, 2025

Top results

In rats with diet-induced obesity, amycretin maintained energy expenditure. (EBioMedicine, 2025)

All 4 studies in people

In people

In adults with type 2 diabetes, four people receiving zenagamtide at 0·4 mg reported serious adverse events.

2026Lancet75 people

In people

In participants with overweight or obesity, amycretin blood concentrations increased in proportion to dose.

2025Lancet144 people

In people

In participants with overweight or obesity, amycretin reduced bodyweight more than placebo at week 36 in Part B.

2025Lancet

In people

Among zenagamtide recipients, 71.4% reported adverse events after treatment.

2026Diabetes, obesity & metabolism42 people

All 6 amycretin studies by area Open the Scientific page

Key amycretin studies

Studies in people come first, then studies in animals and in the lab.

People
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Mora et al. 2026 · Lancet (London, England) · 75 people · cited by 0
9 results
People
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Gasiorek et al. 2025 · Lancet (London, England) · 144 people · cited by 33
2 results
People
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Dahl et al. 2025 · Lancet (London, England) · cited by 59
4 results
People
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Oldenburg et al. 2026 · Diabetes, obesity & metabolism · 42 people · cited by 1
6 results
Animals
The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats
Kuhre et al. 2025 · EBioMedicine · cited by 13
9 results

All 6 Amycretin studies

Amycretin clinical trials

ClinicalTrials.gov lists 31 trials of amycretin. 22 are active or planned, and 0 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

Phase 3not yet recruiting8,500 planned

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Phase 3recruiting5,610 planned

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

Phase 3recruiting1,778 planned

All 4 Amycretin trials

Status and safety

Is amycretin approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

No. Not approved for any use. Its most advanced trial is in phase 3. The FDA and the other sources we use show no approval (as of 27 Oct 2026). Status unknown.

Laws and labels change, so check the regulator for the current status.

Amycretin side effects and safety

PepBank has 12 safety results from studies of amycretin. 12 of them come from studies in people.

Safety results from studies (12)

In the oral amycretin trial, no participants died. (Lancet, 2025)
In adults with type 2 diabetes, four people receiving zenagamtide at 0·4 mg reported serious adverse events. (Lancet, 2026)
Among zenagamtide recipients, 71.4% reported adverse events after treatment. (Diabetes, obesity & metabolism, 2026)
In adults with type 2 diabetes, three people receiving zenagamtide at 1·5 mg reported serious adverse events. (Lancet, 2026)
In adults with type 2 diabetes, two people receiving zenagamtide at 5 mg reported serious adverse events. (Lancet, 2026)
In adults with type 2 diabetes, five people receiving zenagamtide at 10 mg reported serious adverse events. (Lancet, 2026)
In adults with type 2 diabetes, three people receiving zenagamtide at 20 mg reported serious adverse events. (Lancet, 2026)
In adults with type 2 diabetes, one person receiving zenagamtide at 40 mg reported a serious adverse event. (Lancet, 2026)
In the zenagamtide trial, no participants died. (Lancet, 2026)
In adults receiving zenagamtide, reported adverse events were not serious. (Diabetes, obesity & metabolism, 2026)
In adults receiving zenagamtide, no reported adverse events were severe and most were mild. (Diabetes, obesity & metabolism, 2026)
In adults receiving zenagamtide, digestive problems were the most frequent adverse events. (Diabetes, obesity & metabolism, 2026)

See every safety result on the Scientific page

Doses studied (11 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0·4 mg	Human	human	subcutaneous	36 weeks	Randomized trial in people · n = 75	Mora 2026
40 mg	Human	human	subcutaneous	36 weeks	Randomized trial in people · n = 75	Mora 2026
60 mg once weekly	Human	human	subcutaneous	36 weeks	Randomized trial in people	Dahl 2025
20 mg once weekly	Human	human	subcutaneous	36 weeks	Randomized trial in people	Dahl 2025
5 mg once weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people	Dahl 2025
1·25 mg once weekly	Human	human	subcutaneous	20 weeks	Randomized trial in people	Dahl 2025
1·5 mg	Human	human	subcutaneous	36 weeks	Randomized trial in people	Mora 2026
5 mg	Human	human	subcutaneous	36 weeks	Randomized trial in people	Mora 2026
10 mg	Human	human	subcutaneous	36 weeks	Randomized trial in people	Mora 2026
20 mg	Human	human	subcutaneous	36 weeks	Randomized trial in people	Mora 2026
0.3 mg	Human	human	subcutaneous	single dose	Trial in people without random groups · n = 42	Oldenburg 2026

Questions and more

Ask a question about amycretin

The answer links to every study it uses.

What does the evidence say about amycretin?Is amycretin tested in people?Compare with Semaglutide Compare with Liraglutide

Sources

Database: PepBank data for amycretin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about amycretin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Amycretin

Amycretin at a glance